Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CSRWire18h
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Winners and wishers: 8 potential Bay Area drug approvals coming this year
Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
Zacks Investment Research on MSN20h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
How another firm's FDA approval could mean a big win for Denali Therapeutics
Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...
Zacks Investment Research on MSN11h
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...